Oncology Central

Prolonging the survival of advanced pancreatic cancer patients with a novel immunotherapy drug

Researchers from the University of St George’s (London, UK) have recently collaborated with 19 other institutions in Cyprus, Ireland, Italy, Spain and the UK, in a Phase II study investigating the therapeutic potential of IMM-101; a new immunotherapy treatment.
To view restricted content, please:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.